The Supreme Court has declined to impose restrictions on mifepristone, a medication used in abortion procedures, after a federal court had sought to ban its distribution through mail services. The decision maintains current access to the drug while legal challenges continue through the court system.

The case represents the latest legal battle over abortion access since the Supreme Court's 2022 Dobbs v. Jackson decision overturned Roe v. Wade, ending the federal constitutional right to abortion. That ruling returned abortion regulation to individual states, leading to a patchwork of varying laws across the country.

Since the Dobbs decision, numerous states have implemented abortion restrictions ranging from complete bans to various limitations on timing and circumstances. Several states have enacted laws with limited exceptions for cases involving rape, incest, or threats to maternal life. Meanwhile, other states have moved to protect or expand abortion access.

Voter referendums on abortion rights have been held in multiple states since 2022, with many resulting in constitutional protections for abortion access. These ballot measures have generally succeeded in states where they were legally possible to implement.

Mifepristone, approved by the FDA in 2000, is used in combination with another drug for medication abortions and accounts for a significant portion of abortion procedures in the United States. The ongoing legal disputes over the drug's availability have created uncertainty for healthcare providers and patients in states where abortion remains legal.